ChemicalBook > Product Catalog >API >Antineoplastic agents >Tinib Antineoplastic drugs >3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]-

3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]-

Request For Quotation
3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]- Suppliers list
Company Name: Shanghai Beckham Medical Technology Co., Ltd  
Tel: 13816613772
Email: huahero21@sina.com
Company Name: Nantong QuanYi Biotechnology Co., Ltd  
Tel: 0513-66337626 18051384581
Email: sales@chemhifuture.com
Company Name: RD International Technology Co., Limited  
Tel: 18024082417
Email: market@ubiochem.com
Company Name: Guangzhou Ruidi Biotechnology Co., Ltd.  
Tel: 020-82099279 18988941402
Email: sales@ubiochem.com
3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]- Basic information
Product Name:3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]-
Synonyms:3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]-;BOS-172738;DS-5010;Zeteletinib( BOS-172738);Zeteletinib/BOS-172738/ DS-5010;BOS-172738 adipate;CAXM-1190b;DS-5010 adipate
CAS:2216753-97-6
MF:C25H23F3N4O4
MW:500.47
EINECS:
Product Categories:
Mol File:2216753-97-6.mol
3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]- Structure
3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]- Chemical Properties
Boiling point 661.1±55.0 °C(Predicted)
density 1.330±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
form Solid
pka12.23±0.70(Predicted)
color White to light yellow
Safety Information
MSDS Information
3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]- Usage And Synthesis
UsesZeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET, RETV804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib has potent antitumor activity[1][2][3].
in vivo

In a Ba/F3-RET subcutaneous tumor model, Zeteletinib (BOS-172738; DS-5010) dosing at 10 mg/kg twice daily (bid) induces tumor regression[1].
In an LC2/ad NSCLC xenograft model, which has the RET-CCDC6 fusion gene, Zeteletinib dosing at 1 mg/kg thrice daily (tid) induced tumor regression[1].

IC 50PDGFR2
References[1] Yasuyuki Kaneta, et al.Abstract B173: Preclinical characterization and antitumor efficacy of DS-5010, a highly potent and selective RET inhibitor. MOLECULAR CANCERTHERAPEUTICS. January 2018, Volume 17, Issue 1.
[2] Patrick Schoffski, et al. BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 3008-3008.
[3] Kyaw Z Thein, et al. Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer. 2021 Dec;7(12):1074-1088. DOI:10.1016/j.trecan.2021.07.003
3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]- Preparation Products And Raw materials
Tag:3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]-(2216753-97-6) Related Product Information
BOS-172738 hemiadipate 3-Pyridineacetamide, 6-(6,7-dimethoxy-3-quinolinyl)-N-[3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl]- PDGF R beta protein, human (biotinylated, HEK293, His-AVI) Pralsetinib Protein Tyrosine Kinase Compound Library Cofetuzumab